LINK HEALTHCARE SINGAPORE PTE. LTD.

**4.1 Therapeutic indications** Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) at increased risk of toxicity with standard conditioning therapies, and in paediatric patients older than one month with malignant diseases.

<p><strong>4.1 Therapeutic indications</strong></p> <p>Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) at increased risk of toxicity with standard conditioning therapies, and in paediatric patients older than one month with malignant and non-malignant diseases.</p>

<p><strong>4.1 Therapeutic indications</strong></p> <p>Gliolan is indicated in adults for visualisation of malignant tissue during surgery for malignant glioma (WHO grade III and IV).</p>

<p><strong>INDICATIONS</strong></p> <ol> <li><p>For emergency relief of moderate pain by self-administration in conscious haemodynamically stable patients with trauma and associated pain, under supervision of personnel trained in its use (see Dosage and Administration)</p></li> <li><p>For the relief of moderate pain in monitored conscious patients who require analgesia for surgical procedures (See Dosage and Administration)</p></li> </ol> <p><strong>Note:</strong> the total maximum dose must not be exceeded.</p>

<p><strong>4.1 Therapeutic indications</strong><br> SYLVANT is indicated for the treatment of adult patients with multicentric Castleman&rsquo;s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.</p>

<p><strong>4.1 Therapeutic indications</strong><br> SYLVANT is indicated for the treatment of adult patients with multicentric Castleman&rsquo;s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.</p>

<p><strong>4.1 Therapeutic indications</strong></p> <p>Treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.</p>

<p><strong>Indication</strong></p> <p>Cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS).</p>

<p><strong>INDICATIONS</strong></p> <p>Aprotinin is indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.</p>

**INDICATIONS AND USAGE:** NATACYN® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including _Fusarium solani_ keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the _in vitro_ activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established.